Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.

摘要: Aim The evaluation of the efficacy ursodeoxycholic acid (UDCA), pentoxifylline, losartan, and atorvastatin in non-alcoholic steatohepatitis (NASH) treatment. Method 48 patients (25 males/23 females, aged 55 +/- 7.54 years) with histologically confirmed NASH were enrolled between 2001 2005. batch was divided into four groups: A (10 dyslipidemic patients, receiving 10 mg/day), P (13 nonhypertensive/ nondyslipidemic pentoxifylline 400 mg bid), L (12 hypertensive treated 50 mg/day) U nonhypertensive UDCA 15 mg/kg/day). Mean duration treatment 37.8 5.4 weeks. Body mass index, liver biopsy serum level alanine-aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (AP), total cholesterol (TC) triglycerides (TG) determined at inclusion end Liver samples evaluated for necroinflammation, steatosis fibrosis (Brunt's score). Results In group A, a significant reduction ALT, GGT, TC AP noticed. Histology showed diminished steatosis, but no improvement necroinflammation. groups we found mean ALT GGT levels necroinflammatory score. Group presented levels, without necroinflammation or fibrosis. Conclusion Atorvastatin losartan proved to be efficient dyslipidemia- hypertension-associated NASH, by improving both biochemical parameters steatosis/ Pentoxifylline similar non-hypertensive/non-dyslipidemic while did not improve histological score although it improved parameters.